

Applicants: Rene Hen, et al.
Serial No.: Not Yet Known
Filing Date: January 22, 2004
Page 2

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claim 1 (original) A method for determining whether an agent increases brain progenitor cell division comprising: (i) administering the agent to a non-human subject; and (ii) determining whether the resulting brain progenitor cell division in the subject is greater than that in a subject to which the agent was not administered, thereby determining whether the agent increases brain progenitor cell division.

Claim 2-27 (canceled)

Claim 28 (original) A method for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder by administering to an afflicted subject a therapeutically effective amount of an agent determined to have the ability to increase brain progenitor cell division, wherein such ability is determined by a method comprising (i) administering the agent to a non-human subject, and (ii) determining whether the resulting brain progenitor cell division in the subject is greater than that in a subject to which the agent was not administered.

Applicants: Rene Hen, et al.
Serial No.: Not Yet Known
Filing Date: January 22, 2004
Page 3

Claim 29-34 (canceled)

Claim 35 (original) A method for inhibiting the onset of anxiety, depression or a cognitive disorder by administering to a subject in need thereof a prophylactically effective amount of an agent determined as having the ability to increase brain progenitor cell division, wherein such ability is determined by a method comprising (i) administering the agent to a non-human subject, and (ii) determining whether the resulting brain progenitor cell division in the subject is greater than that in a subject to which the agent was not administered.

Claim 36-41 (canceled)

Claim 42 (original) A composition comprising (a) a pharmaceutically acceptable carrier, and (b) an agent determined as having the ability to increase brain progenitor cell division, wherein such ability is determined by a method comprising (i) administering the agent to a non-human subject, and (ii) determining whether the resulting brain progenitor cell division in the subject is greater than that in a subject to which the agent was not administered.

Claim 43-47 (canceled)

Claim 48 (original) An article of manufacture comprising a packaging material having therein an agent determined as

Applicants: Rene Hen, et al.
Serial No.: Not Yet Known
Filing Date: January 22, 2004
Page 4

having the ability to increase brain progenitor cell division, and a label indicating a use of the agent for inhibiting the onset of anxiety, depression, a cognitive disorder or a neurodegenerative disorder in a subject, wherein such ability is determined by a method comprising (i) administering the agent to a non-human subject, and (ii) determining whether the resulting brain progenitor cell division in the subject is greater than that in a subject to which the agent was not administered.

Claim 49-54 (canceled)

Claim 55 (original) An article of manufacture comprising a packaging material having therein an agent determined as having the ability to increase brain progenitor cell division, and a label indicating a use of the agent for treating anxiety, depression, a cognitive disorder or a neurodegenerative disorder in a subject, wherein such ability is determined by a method comprising (i) administering the agent to a non-human subject, and (ii) determining whether the resulting brain progenitor cell division in the subject is greater than that in a subject to which the agent was not administered.

Claim 56-61 (canceled)

Claim 62 (original) A method for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder by administering to an afflicted subject a therapeutically

Applicants: Rene Hen, et al.
Serial No.: Not Yet Known
Filing Date: January 22, 2004
Page 5

effective amount of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.

Claim 63 (original) A method for inhibiting the onset of anxiety, depression or a cognitive disorder by administering to a subject in need thereof a prophylactically effective amount of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.

Claim 64 (original) A composition comprising (a) a pharmaceutically acceptable carrier, and (b) Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.

Claim 65 (original) An article of manufacture comprising a packaging material having therein Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3 and a label indicating a use of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3 for inhibiting the onset of anxiety, depression or a cognitive disorder in a subject.

Claim 66 (original) An article of manufacture comprising a packaging material having therein Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3 and a label indicating a use of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3 for treating anxiety, depression, a cognitive disorder or a neurodegenerative disorder in a subject.